Wakefield Asset Management LLLP Makes New Investment in Catalyst Pharmaceuticals, Inc. $CPRX

Wakefield Asset Management LLLP bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 51,536 shares of the biopharmaceutical company’s stock, valued at approximately $1,203,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Rothschild Investment LLC increased its holdings in shares of Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,520 shares during the period. Advisory Services Network LLC bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at about $39,000. Quarry LP bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at about $40,000. Financial Life Planners bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at about $42,000. Finally, First Horizon Corp bought a new position in Catalyst Pharmaceuticals in the 4th quarter valued at about $52,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Trading Up 0.1%

NASDAQ:CPRX opened at $31.18 on Friday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56. The company has a 50-day moving average of $26.14 and a 200-day moving average of $24.33. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of 17.92, a price-to-earnings-growth ratio of 0.91 and a beta of 0.72.

Analyst Upgrades and Downgrades

CPRX has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Finally, Stephens set a $32.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Three analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $32.17.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).